<code id='1BDB59A558'></code><style id='1BDB59A558'></style>
    • <acronym id='1BDB59A558'></acronym>
      <center id='1BDB59A558'><center id='1BDB59A558'><tfoot id='1BDB59A558'></tfoot></center><abbr id='1BDB59A558'><dir id='1BDB59A558'><tfoot id='1BDB59A558'></tfoot><noframes id='1BDB59A558'>

    • <optgroup id='1BDB59A558'><strike id='1BDB59A558'><sup id='1BDB59A558'></sup></strike><code id='1BDB59A558'></code></optgroup>
        1. <b id='1BDB59A558'><label id='1BDB59A558'><select id='1BDB59A558'><dt id='1BDB59A558'><span id='1BDB59A558'></span></dt></select></label></b><u id='1BDB59A558'></u>
          <i id='1BDB59A558'><strike id='1BDB59A558'><tt id='1BDB59A558'><pre id='1BDB59A558'></pre></tt></strike></i>

          focus

          focus

          author:Wikipedia    Page View:91
          Medicare and money photo illustration.
          Adobe

          Medical technology lobby AdvaMed is fed up with the Centers for Medicare and Medicaid Services. In a letter sent to the agency and shared with STAT, the group urged CMS to act on finalizing a pathway that would make reimbursement for breakthrough devices easier. 

          CMS has been working on implementing the pathway since 2021. A CMS spokesperson told STAT the agency is working “expeditiously” to finalize it. Scott Whitaker, CEO of AdvaMed, said the device industry is tired of waiting.

          advertisement

          “I myself have begun to wonder if they’re really serious about doing this, or if they’re just saying they’re serious about doing it for political reasons or otherwise,” Whitaker told STAT. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Novo Holdings to buy drug manufacturer Catalent in $16.5B deal
          Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

          CarstenSnejbjerg/BloombergLONDON—TheinvestmentarmofNovoNordisk’sparentfoundationisbuyingdrugmanufact

          read more
          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more

          Exact Sciences stock tumbles despite strong cancer detection sales

          ExactSciences'headquartersinMadison,Wis.WikimediaCommonsExactSciencesreportedfirst-quarterrevenuesth